BF
IART icon

BOK Financial’s Integra LifeSciences IART Stock Holding History

BOK Financial’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$174 – 1256
2023
Q4 		$174 Hold
4
– – ﹤0.01% 1248
2023
Q3 		$144 Buy
+4
New +$168 ﹤0.01% 1168

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BOK Financial's IART Position: Q1 2024 in Review

BOK Financial sold out of Integra LifeSciences (IART) in Q1 2024, closing a stake of 4 shares — an estimated $174 sold.

BOK Financial first reported a position in IART in Q3 2023 and held it in 2 quarters. The position peaked at $174 in Q4 2023. 281 funds tracked by Wall St. Rank hold IART as of Q1 2024.

  • BOK Financial reported no remaining Integra LifeSciences position as of Q1 2024 after selling out during the quarter.
  • BOK Financial sold 4 Integra LifeSciences shares in Q1 2024, an estimated $174.
  • BOK Financial first reported a position in Integra LifeSciences in Q3 2023 and held it in 2 quarters.
  • BOK Financial's Integra LifeSciences position peaked at $174 in Q4 2023.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2024.

Based on BOK Financial's 13F filing for Q1 2024, filed 15 May 2024.